Wilate

Wilate is a human coagulation factor VIII and von Willebrand factor concentrate used to manage bleeding disorders. It supports hemostasis in conditions like hemophilia A and von Willebrand disease. This intravenous therapy is derived from human plasma and manufactured in the EU.

Wilate is used to treat and prevent bleeding episodes in patients with hemophilia A or von Willebrand disease. It works by replacing missing or deficient clotting factors in the blood, helping to restore normal clotting function. This medication is particularly useful for managing spontaneous bleeding or during surgical procedures where clotting is critical.

When administered, Wilate helps the blood to clot more effectively by providing the necessary clotting factors. Patients may experience improved control of bleeding episodes and reduced recovery time from injuries or procedures. The effects are typically observed shortly after infusion, supporting hemostasis as needed.

Wilate should be handled with care to avoid contamination or improper administration. Patients should inform their healthcare provider of any known allergies or previous reactions to blood products. Proper storage and handling of the product are essential to maintain its effectiveness and safety.

Wilate may interact with other medications that affect blood clotting, such as anticoagulants or antiplatelet drugs. Patients should discuss their full medication list with their healthcare provider before starting Wilate. Alcohol and certain herbal supplements may also influence clotting and should be used cautiously.